Oncotarget

Reviews:

Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy

Qian Gou, Xin Gong, Jianhua Jin, Juanjuan Shi and Yongzhong Hou _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:60704-60709. https://doi.org/10.18632/oncotarget.19610

Metrics: PDF 2076 views  |   HTML 5340 views  |   ?  


Abstract

Qian Gou1,2,*, Xin Gong2,*, Jianhua Jin1,*, Juanjuan Shi2 and Yongzhong Hou1,2

1Department of Oncology, Affiliated Wujin People’s Hospital, Jiangsu University, Changzhou, 212017, PR China

2Institute of Life Sciences, Jiangsu University, Zhenjiang, 212013, PR China

*These authors contributed equally to this work

Correspondence to:

Yongzhong Hou, email: [email protected]

Keywords: PPARs, ligands, cancer therapy, cell signaling

Received: March 04, 2017     Accepted: July 18, 2017     Published: July 27, 2017

ABSTRACT

Peroxisome-proliferator-activated receptors (PPARs) are nuclear hormone receptors including PPARα, PPARδ and PPARγ, which play an important role in regulating cancer cell proliferation, survival, apoptosis, and tumor growth. Activation of PPARs by endogenous or synthetic compounds regulates tumor progression in various tissues. Although each PPAR isotype suppresses or promotes tumor development depending on the specific tissues or ligands, the mechanism is still unclear. In this review, we summarized the regulative mechanism of PPARs on cancer progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19610